Informations sur le produit
- 2,7-Difluorospiro[9H-fluorene-9,4′-imidazolidine]-2′,5′-dione
- 2,7-Difluorospiro[fluorene-9,5′-imidazolidine]-2′,4′-dione
- 2,7-difluoro-2'H,5'H-spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
- Al-1576
- Al01576
- Alcon 1576
- Hoe-843
- Spiro[9H-fluorene-9,4′-imidazolidine]-2′,5′-dione, 2,7-difluoro-
Imirestat is a synthetic compound that inhibits the activity of reductase enzymes. It has been shown to be effective in treating diabetic neuropathy and metabolic disorders. Imirestat has also been shown to reduce the severity of symptoms in patients with diabetic neuropathy, including foot ulcerations, pain, and autonomic dysfunction. This drug is administered orally and has a half-life of about 8 hours. Imirestat is metabolized by cytochrome P450 enzymes, which are found in liver cells. Imirestat binds to the reductase enzyme and prevents it from reducing NADP+ to NADPH. This in turn reduces the production of glucose from non-carbohydrate sources such as amino acids and glycerol. The reduction in glucose levels may be due to less competition for glucose between insulin-dependent tissues and non-insulin dependent tissues like skeletal muscle or adipose tissue, which produce glucose independently of insulin.
